European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables. Breast Cancer Somatic Genetics Consortium.

2.50
Hdl Handle:
http://hdl.handle.net/10541/91343
Title:
European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables. Breast Cancer Somatic Genetics Consortium.
Authors:
Launonen, V; Laake, K; Huusko, P; Niederacher, D; Beckmann, M W; Barkardottir, R B; Geirsdottir, E K; Gudmundsson, J; Rio, P; Bignon, Y J; Seitz, S; Scherneck, S; Bièche, I; Champème, M H; Birnbaum, D; White, Gavin R M; Varley, Jennifer; Sztán, M; Olah, E; Osorio, A; Benitez, J; Spurr, N; Velikonja, N; Peterlin, B; Winqvist, R
Abstract:
High frequencies of loss of heterozygosity (LOH) in chromosome 11q22-qter have been observed in various malignancies, including breast cancer. Previous studies on breast carcinomas by Winqvist et al (Cancer Res 55: 2660-2664) have indicated that a survival factor gene is located in band 11q23, and that the highly informative microsatellite polymorphism at the APOC3 locus would be a suitable tool to perform more extensive LOH studies. In this European multicentre study, we have examined the occurrence of APOC3 LOH and evaluated the effect of LOH of this chromosomal subregion on the clinical behaviour of the disease in a cohort of 766 breast cancer patients in more detail. LOH for APOC3 was found in 42% of the studied tumours, but it was not found to be significantly associated with any of the studied clinical variables, including cancer-specific survival time or survival time after recurrent/metastatic disease. According to the present findings, the putative survival factor gene on 11q23 is not located close enough to the APOC3 gene, but apparently at a more proximal location.
Affiliation:
Department of Clinical Genetics, University of Oulu/Oulu University Hospital, Finland.
Citation:
European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables. Breast Cancer Somatic Genetics Consortium. 1999, 80 (5-6):879-82 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
May-1999
URI:
http://hdl.handle.net/10541/91343
DOI:
10.1038/sj.bjc.6690435
PubMed ID:
10360669
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorLaunonen, Ven
dc.contributor.authorLaake, Ken
dc.contributor.authorHuusko, Pen
dc.contributor.authorNiederacher, Den
dc.contributor.authorBeckmann, M Wen
dc.contributor.authorBarkardottir, R Ben
dc.contributor.authorGeirsdottir, E Ken
dc.contributor.authorGudmundsson, Jen
dc.contributor.authorRio, Pen
dc.contributor.authorBignon, Y Jen
dc.contributor.authorSeitz, Sen
dc.contributor.authorScherneck, Sen
dc.contributor.authorBièche, Ien
dc.contributor.authorChampème, M Hen
dc.contributor.authorBirnbaum, Den
dc.contributor.authorWhite, Gavin R Men
dc.contributor.authorVarley, Jenniferen
dc.contributor.authorSztán, Men
dc.contributor.authorOlah, Een
dc.contributor.authorOsorio, Aen
dc.contributor.authorBenitez, Jen
dc.contributor.authorSpurr, Nen
dc.contributor.authorVelikonja, Nen
dc.contributor.authorPeterlin, Ben
dc.contributor.authorWinqvist, Ren
dc.date.accessioned2010-02-08T11:13:28Z-
dc.date.available2010-02-08T11:13:28Z-
dc.date.issued1999-05-
dc.identifier.citationEuropean multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables. Breast Cancer Somatic Genetics Consortium. 1999, 80 (5-6):879-82 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid10360669-
dc.identifier.doi10.1038/sj.bjc.6690435-
dc.identifier.urihttp://hdl.handle.net/10541/91343-
dc.description.abstractHigh frequencies of loss of heterozygosity (LOH) in chromosome 11q22-qter have been observed in various malignancies, including breast cancer. Previous studies on breast carcinomas by Winqvist et al (Cancer Res 55: 2660-2664) have indicated that a survival factor gene is located in band 11q23, and that the highly informative microsatellite polymorphism at the APOC3 locus would be a suitable tool to perform more extensive LOH studies. In this European multicentre study, we have examined the occurrence of APOC3 LOH and evaluated the effect of LOH of this chromosomal subregion on the clinical behaviour of the disease in a cohort of 766 breast cancer patients in more detail. LOH for APOC3 was found in 42% of the studied tumours, but it was not found to be significantly associated with any of the studied clinical variables, including cancer-specific survival time or survival time after recurrent/metastatic disease. According to the present findings, the putative survival factor gene on 11q23 is not located close enough to the APOC3 gene, but apparently at a more proximal location.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshApolipoproteins C-
dc.subject.meshBreast Neoplasms-
dc.subject.meshChromosomes, Human, Pair 11-
dc.subject.meshEurope-
dc.subject.meshFemale-
dc.subject.meshGenetic Markers-
dc.subject.meshHumans-
dc.subject.meshLoss of Heterozygosity-
dc.subject.meshMiddle Aged-
dc.titleEuropean multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables. Breast Cancer Somatic Genetics Consortium.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Genetics, University of Oulu/Oulu University Hospital, Finland.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.